title: JAK-2V617F mutation in RARS-t: a target for Imatinib therapy?
authors.forename: Elisa
authors.initials: E
authors.lastname: Cannizzo
authors.forename: Giovanni
authors.initials: G
authors.lastname: Carulli
authors.forename: Antonio
authors.initials: A
authors.lastname: Azzarà
authors.forename: Sara
authors.initials: S
authors.lastname: Galimberti
authors.forename: Alessandra
authors.initials: A
authors.lastname: Zucca
authors.forename: Mario
authors.initials: M
authors.lastname: Petrini
mesh_terms: D000368:Aged; D019943:Amino Acid Substitution; D000753:Anemia, Refractory / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use*; D010976:Platelet Count; D017354:Point Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C507924:JAK2 protein, human; D053614:Janus Kinase 2